{
    "2019-01-19": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Lilly: Phase 3 Soft Tissue Sarcoma Study Fails To Meet Primary Endpoints",
                "features": {
                    "keywords": [
                        "Phase 3",
                        "Soft Tissue Sarcoma",
                        "Study Fails",
                        "Primary Endpoints"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "Eli Lilly’s Sarcoma Drug Combo Proves Ineffective in Trials",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Sarcoma",
                        "Drug Combo",
                        "Ineffective",
                        "Trials"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-19",
                "original_text": "Eli Lilly News: LLY Stock Falls on Sarcoma Study Failure",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "LLY Stock",
                        "Falls",
                        "Sarcoma",
                        "Study Failure"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-25",
                "original_text": "Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients",
                "features": {
                    "keywords": [
                        "Phase 3",
                        "REACH-2 Trial",
                        "CYRAMZA",
                        "Improvement",
                        "Overall Survival",
                        "Hepatocellular Carcinoma"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}